This will be a single-arm, multicenter, prospective, observational, real-world study and the data source is the patients' medical record at each site. A total of 78 patients will be enrolled in the study.
Patients with newly diagnosed previously untreated resectable NSCLC (tumors ≥ 4 cm and/or node positive) and no known EGFR mutations or ALK rearrangements prescribed with durvalumab as per local prescriber information.
Provision of signed, written and dated informed consent
Presence of unresectable or metastatic disease.
Prior treatment with durvalumab for any other indications
Requires concurrent treatment for cancers other than resectable NSCLC
Concurrently participating in any other clinical trial